|
1
|
Miyakis S, Lockshin MD, Atsumi T, et al:
International consensus statement on an update of the
classification criteria for definite antiphospholipid syndrome
(APS). J Thromb Haemost. 4:295–306. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Meroni PL, Borghi MO, Raschi E and Tedesco
F: Pathogenesis of antiphospholipid syndrome: understanding the
antibodies. Nat Rev Rheumatol. 7:330–339. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Soltesz P, Der H, Veres K, et al:
Immunological features of primary anti-phospholipid syndrome in
connection with endothelial dysfunction. Rheumatology (Oxford).
47:1628–1634. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Silveira LH, Hubble CL, Jara LJ, et al:
Prevention of anticardiolipin antibody-related pregnancy losses
with prednisone and aspirin. Am J Med. 93:403–411. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cowchock FS, Reece EA, Balaban D, Branch
DW and Plouffe L: Repeated fetal losses associated with
antiphospholipid antibodies: a collaborative randomized trial
comparing prednisone with low-dose heparin treatment. Am J Obstet
Gynecol. 166:1318–1323. 1992. View Article : Google Scholar
|
|
6
|
Ghazeeri GS and Kutteh WH: Immunological
testing and treatment in reproduction: frequency assessment of
practice patterns at assisted reproduction clinics in the USA and
Australia. Hum Reprod. 16:2130–2135. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pierangeli SS, Espinola R, Liu X, Harris
EN and Salmon JE: Identification of an Fc gamma
receptor-independent mechanism by which intravenous immunoglobulin
ameliorates antiphospholipid antibody-induced thrombogenic
phenotype. Arthritis Rheum. 44:876–883. 2001. View Article : Google Scholar
|
|
8
|
Branch DW, Peaceman AM, Druzin M, et al: A
multicenter, placebo-controlled pilot study of intravenous immune
globulin treatment of antiphospholipid syndrome during pregnancy.
The Pregnancy Loss Study Group. Am J Obstet Gynecol. 182:122–127.
2000. View Article : Google Scholar
|
|
9
|
Sebire NJ, Fox H, Backos M, Rai R,
Paterson C and Regan L: Defective endovascular trophoblast invasion
in primary antiphospholipid antibody syndrome-associated early
pregnancy failure. Hum Reprod. 17:1067–1071. 2002. View Article : Google Scholar
|
|
10
|
Alalaf S: Bemiparin versus low dose
aspirin for management of recurrent early pregnancy losses due to
antiphospholipd antibody syndrome. Arch Gynecol Obstet.
285:641–647. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stephenson MD, Ballem PJ, Tsang P, et al:
Treatment of antiphospholipid antibody syndrome (APS) in pregnancy:
a randomized pilot trial comparing low molecular weight heparin to
unfractionated heparin. J Obstet Gynaecol Can. 26:729–734.
2004.
|
|
12
|
Salmon JE and Girardi G: Theodore E.
Woodward Award: antiphospholipid syndrome revisited: a disorder
initiated by inflammation. Trans Am Clin Climatol Assoc.
118:99–114. 2007.PubMed/NCBI
|
|
13
|
Hochart H, Jenkins PV, Smith OP and White
B: Low-molecular weight and unfractionated heparins induce a
downregulation of inflammation: decreased levels of proinflammatory
cytokines and nuclear factor-kappaB in LPS-stimulated human
monocytes. Br J Haematol. 133:62–67. 2006. View Article : Google Scholar
|
|
14
|
Wang L, Brown JR, Varki A and Esko JD:
Heparin’s anti-inflammatory effects require glucosamine
6-O-sulfation and are mediated by blockade of L- and P-selectins. J
Clin Invest. 110:127–136. 2002.
|
|
15
|
Guerin J, Sheng Y, Reddel S, Iverson GM,
Chapman MG and Krilis SA: Heparin inhibits the binding of beta
2-glycoprotein I to phospholipids and promotes the plasmin-mediated
inactivation of this blood protein. Elucidation of the consequences
of the two biological events in patients with the anti-phospholipid
syndrome. J Biol Chem. 277:2644–2649. 2002. View Article : Google Scholar
|
